Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity

Article abstract of DOI:10.1016/j.ejmech.2018.08.007

The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme that has been implicated as an important drug target in various therapeutic areas, including neurological disorders (Down syndrome, Alzheimer's disease), oncology, and

Full text of DOI:10.1016/j.ejmech.2018.08.007

Accepted Manuscript
Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-
cell proliferation activity
Kunal Kumar, Peter Man-Un Ung, Peng Wang, Hui Wang, Hailing Li, Mary K.
Andrews, Andrew F. Stewart, Avner Schlessinger, Robert J. DeVita
PII:
S0223-5234(18)30665-2
10.1016/j.ejmech.2018.08.007
EJMECH 10618
DOI:
Reference:
To appear in: European Journal of Medicinal Chemistry
Received Date: 21 May 2018
Revised Date: 1 August 2018
Accepted Date: 2 August 2018
Please cite this article as: K. Kumar, P. Man-Un Ung, P. Wang, H. Wang, H. Li, M.K. Andrews, A.F.
Stewart, A. Schlessinger, R.J. DeVita, Novel selective thiadiazine DYRK1A inhibitor lead scaffold with
human pancreatic β-cell proliferation activity, European Journal of Medicinal Chemistry (2018), doi:
10.1016/j.ejmech.2018.08.007.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT
Novel Selective Thiadiazine DYRK1A Inhibitor
Lead Scaffold with Human Pancreatic β-cell
Proliferation Activity
Kunal Kumar1,2,†, Peter Man-Un Ung2,†, Peng Wang3, Hui Wang1,2, Hailing Li1,2, Mary K.
Andrews1,2, Andrew F. Stewart3, Avner Schlessinger2*, Robert J. DeVita1,2*
1 Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029,
USA
2 Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New
York, NY 10029, USA
3 Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New
York, NY 10029, USA
† Equal contribution
* Corresponding authors: Robert J. DeVita. E-mail: robert.devita@mssm.edu. Phone: 212-659-
5542; Avner Schlessinger. E-mail: avner.schlessinger@mssm.edu. Phone: 212-241-3321
KEYWORDS: Dual-specificity Tyrosine-Regulated Kinases (DYRKs), DYRK1A inhibitor,
Structure Activity Relationship Study, Selectivity, Proliferation, Diabetes

ACCEPTED MANUSCRIPT
ABSTRACT
The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme
that has been implicated as an important drug target in various therapeutic areas, including
neurological disorders (Down syndrome, Alzheimer’s disease), oncology, and diabetes
(pancreatic β-cell expansion). Current small molecule DYRK1A inhibitors are ATP-competitive
inhibitors that bind to the kinase in an active conformation. As a result, these inhibitors are
promiscuous, resulting in pharmacological side effects that limit their therapeutic applications.
None are in clinical trials at this time. In order to identify a new DYRK1A inhibitor scaffold, we
constructed a homology model of DYRK1A in an inactive, DFG-out conformation. Virtual
screening of 2.2 million lead-like compounds from the ZINC database, followed by in vitro
testing of selected 68 compounds revealed 8 hits representing 5 different chemical classes. We
chose to focus on one of the hits from the computational screen, thiadiazine 1 which was found
to inhibit DYRK1A with IC50 of 9.41 µM (Kd = 7.3 µM). Optimization of the hit compound 1,
using structure-activity relationship (SAR) analysis and in vitro testing led to the identification of
potent thiadiazine analogs with significantly improved binding as compared to the initial hit (Kd
= 71-185 nM). Compound 3-5 induced human β-cell proliferation at 5 µM while showing
selectivity for DYRK1A over DYRK1B and DYRK2 at 10 µM. This newly developed DYRK1A
inhibitor scaffold with unique kinase selectivity profiles has potential to be further optimized as
novel therapeutics for diabetes.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT
INTRODUCTION
The Dual-specificity Tyrosine-Regulated Kinases (DYRKs) belong to the CMCG family
of eukaryotic protein kinases, which include the CDK-like kinases (CLKs), Glycogen Synthase
Kinases 3 (GSK3s), Cyclin Dependent Kinases (CDKs) and Mitogen-Activated Protein Kinases
(MAPKs). DYRK family proteins self-activate by auto-phosphorylation of the conserved
tyrosine residue in the activation loop, then subsequently phosphorylate substrates only on serine
and threonine residues.[1-3] The DYRK family consists of five subtypes including 1A, 1B, 2, 3
and 4. Among them, DYRK1A is the most extensively studied subtype. It is ubiquitously
expressed and has been shown to play an important role in brain development and function,[4]
neurodegenerative diseases,[5, 6] tumorigenesis, apoptosis,[7, 8] and human pancreatic
proliferation[9-12].
β-cell
Regulated expression of DYRK1A during fetal, postnatal life, as well as in adults is
essential for normal neuronal development and brain function. DYRK1A is located in the Down
Syndrome Critical region (DSCR) on human chromosome 21, a genomic region that has an
important role in pathogenesis of Down Syndrome (DS), one of the most common and frequent
human genetic disorders.[1, 13] Overexpression of DYRK1A in mouse and Drosophila models
mimics the neurodevelopmental abnormalities associated with DS.[4, 5, 14, 15] Recent evidence
has also implicated DYRK1A in the tau dysfunction and tau pathology of Alzheimer’s disease
(AD), dementia with Lewy bodies, and Parkinson’s disease.[5, 6, 16] In addition, it has been
reported that DYRK1A is overexpressed in various tumors such as, ovarian cancer, colon cancer,
lung cancer and pancreatic cancer, signifying its role in tumorigenesis and uncontrolled cell
proliferation.[7, 8] Inhibition of DYRK1A has been reported to promote EGFR degradation and
reduce EGFR-dependent tumor growth in glioblastoma.[17] Furthermore, DYRK1A inhibition

ACCEPTED MANUSCRIPT
induces activation of caspase-9 which leads to massive apoptosis in specific cancer cell
types.[18] Recently, DYRK1A has been shown to be involved in molecular pathways relevant to
human pancreatic
β-cell proliferation, making it a potential therapeutic target for β-cell
regeneration in Type 1 and Type 2 diabetes.[9-12, 19]
DYRK1A has attracted increasing interest as a potential therapeutic target because it has
been implicated, for example, in neurodegenerative disease, cancer and diabetes. A significant
amount of research has been carried out to not only understand its underlying role in diseases,
but also in identifying novel DYRK1A inhibitors.[1, 4, 6-10, 12] Several DYRK1A inhibitors
have been identified and characterized from natural sources as well as from small molecule drug
discovery programs. Among known DYRK1A inhibitors, harmine and its analogues (β-
carbolines) are the most studied and remain the most potent and orally bioavailable class of
inhibitors available.[1, 6] Apart from harmine, epigallocatechin (EGCG) and other flavan-3-
ols,[20, 21] leucettines,[22, 23] quinalizarine,[24] peltogynoids Acanilol A and B,[25]
benzocoumarins (dNBC),[26] indolocarbazoles (Starosporine, rebeccamycin and their
analogues),[27] are other natural products that have been shown to inhibit DYRK1A and other
kinases. Among the other scaffolds identified from small molecule drug discovery,
GNF4877,[10] INDY,[15] DANDY,[28] and FINDY,[29] pyrazolidine-diones,[30, 31] amino-
quinazolines,[32] meriolins,[33-35] pyridine and pyrazines,[36] chromenoindoles,[37] 11H-
indolo[3,2-c]quinoline-6-carboxylic acids,[38] thiazolo[5,4-f]quinazolines (EHT 5372),[39, 40]
CC-401[19] and 5-iodotubercidin[12, 41] showed potent DYRK1A activity with varying degrees
of kinase selectivity.
Recently, using a phenotypic luciferase reporter high-throughput small-molecule screen
(HTS), our group identified harmine as a new class of compounds that cause ~10-15-fold

ACCEPTED MANUSCRIPT
induction in human pancreatic
human -cell expansion.[9] DYRK1A was defined as the likely target of harmine through
genetic silencing and other studies, likely working through the Nuclear Factors of Activated T-
cells (NFAT) family of transcription factors as mediators of human -cell proliferation and
differentiation.[9] Using three different mouse, rat and human pancreatic islet models, we have
shown that harmine is able to induce -cell proliferation and increase islet mass, and to improve
β-cell proliferation, which is in the relevant range for therapeutic
β
β
β
glycemic control in mice transplanted with a marginal mass of human islets in vivo.[9]
Since DYRK1A and NFATs are widely expressed in other cell types, harmine analogs
are known to hit off-targets that lead to pharmacological side effects, including CNS activity,
thereby limiting its therapeutic utility and potential for pharmaceutical development for a chronic
disease like diabetes. To counter these suboptimal selectivity and safety profiles, we were
interested in identifying novel DYRK1A inhibitor scaffolds with the potential for a unique
binding mode to DYRK1A other than the canonical ATP-competitive binding mode. As a
starting point, we proposed to use a computational approach to model DYRK1A in an inactive
conformation, the DFG-out conformation,[42],[43, 44] and to identify new inhibitors with the
potential for improved selectivity and safety profile as compared to known DYRK1A type-I
inhibitors.
Herein, we report the identification of potent and novel DYRK1A inhibitor scaffolds,
using an integrated computational modeling and medicinal chemistry approach (Figure 1A). We
used DFGmodel,[42] a computational method for modeling the inactive kinase conformations, to
model DYRK1A. Virtual screening of lead-like molecules (2,268,809 compounds) against the
inactive DYRK1A models followed by binding and functional assays identified a novel
DYRK1A inhibitor hit scaffold, 1 with IC50 of 9.41 µM (Kd = 7.3 µM). We also describe our hit-

ACCEPTED MANUSCRIPT
to-lead medicinal chemistry studies of this scaffold compound which led to the identification of a
highly potent thiadiazine lead inhibitor 3-5 with 90-fold improved DYRK1A binding as
compared to the initial hit, compound 1, and authentic human pancreatic β-cell proliferation with
impressive selectivity for DYRK1A over the closely related DYRK1B and DYRK2.
RESULTS AND DISCUSSION
DYRK1A Kinase Modeling. All currently known inhibitor-bound DYRK1A crystal structures
adopt the DFG-in conformation, confirming these inhibitors as canonical type-I, ATP-
competitive inhibitors.[15, 45-47] We anticipated that DYRK1A inhibitors that are identified
from alternative kinase conformations could possess novel chemical scaffolds as well as exhibit
different kinase selectivity and safety profiles as compared to type-I inhibitors. As a starting
point, we constructed models of DYRK1A in the DFG-out conformation for virtual screening to
identify hits with novel binding modes. Specifically, we applied DFGmodel, a homology
modeling pipeline recently-developed in one of our labs (Figure 1B).[42] In brief, DFGmodel
takes the amino acid sequence or known DFG-in structure of the target protein (if available) as
input, and relies on a curated set of inactive kinase structures covering a range of unique
conformations as modeling templates, to generate multiple DFG-out models. This method also
models the rigid-body movement of the small-lobe observed in the DFG-out conformations of
protein kinases. Fifty initial DFG-out DYRK1A models were generated with MODELLER[48]
and evaluated and ranked with Z-DOPE, a normalized atomic distance-dependent statistical
potential based on known protein structures[49]. The newly generated DYRK1A DFG-out
models had a median Z-DOPE score of -0.93
analysis.[42, 50]
± 0.05, suggesting that they are reliable for further

ACCEPTED MANUSCRIPT
Our model’s binding site comprises a portion of the ATP-binding pocket, which is
partially blocked by the DFG-motif in the DFG-out conformation, and the DFG-pocket, which
was previously occupied by the DFG-Phe (Phe308) side-chain of the known DFG-in structures
(Figure 1C). Our protocol selects final models based on the size of the ligand-binding site.[42]
Notably, a key feature of DYRK1A is its gatekeeper residue Phe238, which is located at
the narrow channel bridging the ATP-binding pocket and the DFG-pocket (Figure 1D). Several
first-generation type-II kinase inhibitors such as imatinib and sorafenib have low affinity for
kinases with large gatekeeper residues, such as Phe and Met, but have strong preference for
kinases with small-sized gatekeeper residues (Thr and Val), which are over-represented in
tyrosine kinases such as ABL and VEGFR2.[42, 43] Recent studies showed that kinases with
large gatekeeper residues can be targeted with non-type-I kinase inhibitors (e.g., CDK8)[51, 52],
suggesting that DYRK1A might be amenable to structure-based discovery of unique inhibitors
with alternative binding modes.
Virtual screening of DYRK1A structural models. We conducted virtual screening to each of
the 10 DFG-out DYRK1A models using the ZINC12[53] lead-like small molecule library (2.2
million “available now”). We and others have shown that ligand enrichment for protein kinases
is significantly improved when considering multiple conformations of homology models rather
than a single structure.[42, 54, 55] The screen ranked molecules in the library according to their
docking scores. To condense the results from these 10 models, we considered molecules that are
in the 93rd percentile in 5 of 10 models (approximately 1,000 molecules). We clustered these
molecules by their chemical similarity using the ECFP4 fingerprints with a Tanimoto coefficient
(Tc) cutoff of 0.4 and visually inspected the predicted binding poses. We used the following
considerations for selecting compounds for experimental testing: 1) the compound docks in the

ACCEPTED MANUSCRIPT
DFG-pocket; 2) potential for interaction with the amide backbone of the hinge-binding region,
the αC-helix’s conserved glutamate residue (E203), or the DFG-Asp amide backbone (D307); 3)
the compound samples unique chemical scaffolds not known as DYRK1A inhibitors; 4)
scaffolds with drug-like properties[56]; and 5) the compound is synthetically accessible with few
steps. Finally, we removed likely false positives, such as those predicted hits with unlikely
tautomers or strained conformations. Although the compounds were predicted based on a DFG-
out model, some of the compounds may dock well to DFG-in conformations, increasing our
confidence in the prediction that they are DYRK1A inhibitors. For example, Harmine, a known
type-I kinase inhibitor of DYRK1A docks well to DFG-out models with various docking
programs (Figure 1C, D).
Figure 1. DYRK1A DFG-out models. (A) Strategy from computational modeling to
experimental testing to identify DYRK1A inhibitor hit 1. (B) The DFG-in crystal structure and
DFG-out model are shown in ribbon. The large-lobe of the two conformations is identical (gray);
The small-lobe of the DFG-out structure and DFG-in model are shown in pink and cyan ribbons,
respectively. (C) The conformational change between the DFG-in (cyan sticks) and DFG-out

ACCEPTED MANUSCRIPT
(pink sticks) states is shown. The type-I inhibitor harmine (cyan sticks) binds the ATP-binding
site of DYRK1A in the DFG-in structure. (D) The electrostatic potential of the surface of the
ligand-binding pocket in the DFG-out conformation is shown, with the DFG-pocket highlighted
in blue ellipse.
We purchased 68 commercially available compounds for testing of in vitro DYRK1A
activity at 30 µM concentration using Life Technologies FRET-based LanthaScreen® Eu Kinase
Binding Assay[57] (Figure 1A). Eight compounds showed inhibition of DYRK1A activity in
30-80% range at 30 µM (hit-rate of 11.7%). Of the 8 initial hits, we focused on compound 1
(CAS 931037-76-2), a 1,3,4-thiadiazine, with IC50 of 9.41 µM against DYRK1A. These data
were further confirmed by a second, orthogonal assay KINOMEscan®[58] (DiscoverX) that
quantifies DYRK1A binding through a sensitive qPCR method. The results obtained were
consistent with those of the Life Technologies inhibition assay with the Kd of 7.3 µM for
compound 1 in the DiscoverX assay.
Hit-to-lead optimization and SAR studies. We confirmed the structure of the hit 1,3,4-
thiadiazine 1 (HCl salt) by independent synthesis (Scheme 1) and comparison to the
commercially purchased sample. NMR, LC-MS, and biological data confirmed the identity of
the hit 1 in all aspects (Materials and Methods). The neutral analogue of compound 1 (3-1, non-
salt) was found to have comparable DYRK1A activity with Kd of 4.5 µM (IC50 = 4.32 µM)
(Table 1). With a confirmed scaffold in hand, we began a hit-to-lead SAR study to improve its
DYRK1A binding potency and in vitro biological activity. We performed systematic structural
modifications at the 2-amino position, keeping the rest of the molecule intact (Figure 2).

ACCEPTED MANUSCRIPT
Figure 2. Summary of the SAR studies of compound 1.
The hit 1,3,4-thiadiazine compound 1 and its analogues were synthesized by the protocol
outlined in Scheme 1.[59] Acylation of commercially available 2-benzimidazolone with
chloroacetyl chloride in the presence of AlCl3 gave compound 2 in 99% crude yield.[60]
Subsequently, the α-chloroketone 2 underwent smooth cyclo-condensation[59] with purchased or
synthesized thiosemicarbazides (see Supporting Information) containing various R-groups to
afford the desired thiadiazine analogues (27 compounds, Table 1) in range of 23-90% yield.
Scheme 1. The Synthesis of 1,3,4-thiadiazines 3. i) Hydrazine monohydrate (2.0 eq.), Et2O, rt,
12 h, 39-99%; ii) Chloroacetyl chloride (2.0 eq.), AlCl3 (2.6 eq.), DCE, rt, 12 h, 99%; iii) 1-2

ACCEPTED MANUSCRIPT
(1.1 eq.), DMF/AcOH, rt, 24 h, 23-90%; iv) K2CO3 (0.15 eq.), H2O2 (50% aq. Solution), DMSO,
rt, 12 h, 42%.
We first investigated the effect of various 2-substituted benzylamino groups on the
DYRK1A binding activity as shown in Table 1. We found that DYRK1A binding activity is
highly sensitive to the substitution pattern of the 2-benzylamino moiety. Notably, we observed
that the introduction of fluorobenzylamino (3-2 to 3-4) and chlorobenzylamino (3-5 to 3-7)
substituents at the 2-position of the thiadiazine improved the DYRK1A binding affinity of the hit
3-1 by 25- to 60-fold. Among these analogs, p-substituted benzylamino thiadiazines showed
better DYRK1A binding as compared to their respective o- and m-substituted benzylamino
analogues. Specifically, compounds 3-2 and 3-5 bearing
p–chloro and p-fluorobenzylamino
showed 24- to 60-fold improvement with Kd‘s of 185 nM and 71 nM, respectively, as compared
to the original hit 1 (Kd = 7300 nM) and 3-1 (Kd = 4500 nM). However, in case of
trifluoromethyl-substituted benzylamino (3-8 to 3-10) and cyano-substituted benzylamino
thiadiazine analogues (3-11 to 3-12), the improvement in binding activity was not as significant.
Two exceptions are for m-trifluorobenzylamino thiadiazine (3-9) and m-cyanobenzylamino
thiadiazine analogues (3-12) with Kd of 660 and 320 nM, respectively, a 7- to 15-fold
improvement in DYRK1A binding as compared to original hit 3-1. For trifluoromethyl-
substituted (3-8 to 3-10) and cyano substituents, the
significantly more potent than corresponding - and
from those of halogen substituents, which showed improved DYRK1A binding for the
substituted benzyl group as compared to their respective - and -analogs.
m
-substituted benzyl thiadiazines were
o
p-substituted analogs. These SAR differ
p
-
o
m

ACCEPTED MANUSCRIPT
We also introduced pyridylmethylamino substituents at the thiadiazine 2–position to
study their effects on DYRK1A binding as well as to reduce the clogP of compound 3-1 (clogP =
2.83). Two pyridyl analogs (3-13 and 3-14) showed improved DYRK1A binding affinity
compared to the hit 3-1 with reduce lipophilicity (3-13 clogP = 1.41). For example, compound 3-
13 with 2-(pyridine-3-yl)methylamino substituent had binding affinity Kd of 860 nM, a 5-fold
increase over compound 3-1. In addition, compound 3-15 bearing more polar m-carboxamide
substituted benzyl group was synthesized by hydrolysis of the corresponding cyano derivative
(3-12) using basic hydrogen peroxide solution (Scheme 1).[61] This compound was found to
have improved DYRK1A binding (Kd = 440 nM) as compared to hit compound 3-1 with ~10-
fold increase in Kd.
We next examined the effect of introducing methyl[62] at the
α-carbon of the
benzylaminothiadiazine 3-1. The 2-( -methyl)benzylamino thiadiazine compound (3-16) was
α
well tolerated, providing 4-fold improvement in the DYRK1A binding assay (Kd = 1100 nM).
Since 4-fluorobenzylamino substituent at the 2-position improved DYRK1A binding, we
synthesized 2-(4-fluoro(α-methyl))benzylamino thiadiazine (3-17). Surprisingly, introduction of
fluorine substituent reduced the DYRK1A binding by half with Kd of 2300 nM. We continued to
study the effects of combinations of benzyl substituents to further develop our binding models
and SAR studies.
Last, we investigated the effect of changing the carbon chain length between the 2-amino
and the phenyl group. Since m-trifluoromethylbenzylamino and m-cyanobenzylamino
substituents were important to improve binding affinity, we synthesized
m-phenylamino
substituted thiadiazines (3-19 to 3-21) that are commonly found in DFG-out specific kinase
inhibitors.[63] The 2-phenyl substituted thiadiazines did not show any improvement in binding

ACCEPTED MANUSCRIPT
affinity as compared to their superior benzylic analogs, except for compound 3-21 (Kd = 3800
nM). Increasing the carbon chain length between the amino and the phenyl group by one carbon
atom, resulted in improvement in binding affinity for 2-(2-phenylethyl)amino thiadiazine (3-22)
(Kd = 1600 nM), a 3-fold increase in activity as compared to the compound 3-1. Introduction of
methyl
β
to 2-amino (3-23), further improved the binding affinity of the compound by 5-fold.
-(2-(pyridine-2-yl)ethyl) (3-24) and -(2-(pyridine-3-yl)ethyl) (3-25)
Corresponding
N
N
thiadiazine analogues of compound 3-22 did not show any improvement in DYRK1A binding
affinity as compared to their phenyl analogues. However, all of these analogues had 4- to 5-fold
more potent Kd’s as compared to the hit compound 3-1.
Bulky substituents, including naphthylamino groups (3-26 to 3-28) at the thiadiazine 2-
position did not improve binding affinity. Among all the analogues prepared, 4–chloro (3-2) and
4-fluoro (3-5) benzylamino thiadiazines showed superior affinity to DYRK1A for the analogues
prepared.

ACCEPTED MANUSCRIPT
Table 1.
Percent Inhibition at 30 µM and Kd of the Thiadiazine DYRK1A Inhibitors
H
N
O
N
N
H
N
R
S
N
H
Screening (30 M)
LifeTecha DiscoverXb
Screening (30 M)
LifeTecha DiscoverXb
Kd (nM)c
Kd (nM)c
R
R
Compound
Compound
CONH2
7300
1
43
81
3-15
3-16
-
-
440
(9415)d
HCl salt
4500
(4320)d
3-1
-
-
57
3.7
1100
3-2
3-3
93
-
19
-
185
420
3-17
3-18
-
-
2300
Cl
Cl
F
39
41
19000
F
Cl
3-4
3-5
-
-
840
71
3-19
3-20
-
-
-
-
7000
CF3
CN
95
8.9
14000
F
F
3-6
-
-
900
3-21
-
-
3800
F
3-7
3-8
-
-
810
3-22
3-23
61
-
0.5
-
1600
950
53
40
13000
CF3
CF3
3-9
20
23
660
3-24
87
8.4
1600
CF3
N
3-10
3-11
24
47
38
12
7700
6200
3-25
3-26
-
-
2200
n.d.
N
24
64
CN
CN
3-12
69
12
320
3-27
3-28
11
32
36
82
7300
n.d.
3-13
3-14
74
-
4.2
-
860
N
2200
N
n.d.= not determined
a
‘% DYRK1A inhibition’ of tested compound at 30 µM, where higher values indicates
stronger affinity

ACCEPTED MANUSCRIPT
b
‘% DMSO Control’ of tested compound at 30 µM (n = 2), where lower values indicate
stronger affinity
c Kd values are determined using eleven serial three fold dilutions (in duplicate)
d Value in parenthesis is IC50 determined at Life Technologies
Human β-cell proliferation assay: As mentioned earlier, DYRK1A inhibition has been reported
to drive human pancreatic β-cell proliferation,[9, 10, 11, 19] thus making it a potential
therapeutic target for both Type 1 and Type 2 diabetes. Therefore, the effect of the most active
DYRK1A inhibitor 3-5 on human β-cell proliferation was investigated using our reported assay
protocols.[9] Compound 3-5 induced human β-cell proliferation at 5 µM, as compared to
vehicle-treated cells, as quantified by increased KI67 labeling of insulin-labeled cells (Figure
3A, 3B). These data indicate that this 1,3,4-thiadiazine analogue induces β-cell proliferation
similar to the positive control harmine. This confirms that our 1,3,4-thiadiazine scaffold have the
potential for further improvement as therapeutic agents for diabetes treatment.
Figure 3: Analysis of DYRK1A inhibitors on human β-cell proliferation. (A) Human β-cell
proliferation assay using 5 µM of compound 3-5 and DMSO as negative control. (B) A
representative example from A of a KI67. Error bars indicate sem *P < 0.05. A minimum of
1,000 beta cells was counted from each of 4 different human islet donors.

ACCEPTED MANUSCRIPT
Kinase selectivity profile against DYRK family kinases: In order to assess the kinase selectivity
profile of these inhibitors, we carried out kinase binding assays of compound 3-5 and harmine
(CAS 442-51-3) on the closely related DYRK1A, DYRK1B, and DYRK2 at 10 µM (Table 2)
using the DiscoverX assay technology. Harmine inhibited DYRK1B and DYRK2 (<20% activity
remaining) in addition to DYRK1A (< 1%) at 10 µM, exhibiting poor selectivity as previously
reported. In contrast, the thiadiazine scaffold lead compound 3-5 exhibited an impressive
selectivity for DYRK1A (4.3% remaining) as compared to DYRK1B (31% remaining) and
DYRK2 (55% remaining). These data indicate the possibility that the selectivity is a result of a
different binding mode as compared to canonical ATP-competitive inhibitors for DYRK1A, like
harmine, which show reduced selectivity for closely related kinases.
Table 2.
Selectivity Profile of Harmine and Thiadiazine 3-5 against the DYRK-family of Protein
Kinasesa
Target
Harmine
3-5
4.3
31
DYRK1A
DYRK1B
DYRK2
0
6.1
3.2
55
a
Compounds were screened at 10 µM using DiscoverX KINOMEscan®. Results for primary
screen binding interactions are reported as '% DMSO Ctrl', where lower values indicate stronger
inhibition.
CONCLUSIONS

ACCEPTED MANUSCRIPT
We have described the identification of a novel DYRK1A inhibitor scaffold using an
integrated computational modeling and medicinal chemistry optimization approach. We
developed a homology model of DYRK1A in the inactive conformation using a newly developed
computational protocol. This DYRK1A structural model revealed a flexible and hydrophobic
inhibitor-binding site with a weakly negative electrostatic potential. Virtual screening of this
binding site for lead-like compounds from the ZINC12 database, followed by chemical biology
and medicinal chemistry evaluation led to the selection of 68 compounds for in vitro assay of
DYRK1A binding. 8 compounds were identified with DYRK1A binding in the range of 30-80%
at a concentration of 30 µM, exhibiting a high hit-rate for a discovery campaign using a
homology model. From these initial hits, compound 1 was titrated and found to inhibit DYRK1A
with IC50 of 9.41 µM (Kd = 7.3 µM), exhibiting a unique scaffold for DYRK1A kinase inhibitors.
The preliminary hit-to-lead medicinal chemistry was performed on 2-benzylamino-5-
(benzo[d]imidazol-2(3H)-one)-6H-1,3,4-thiadiazine (3-1), to optimize the 2-benzylamino
substituents through systematic modifications. We observed that the substitution pattern of the 2-
benzylamino group substantially impacts the DYRK1A binding activity of this lead series. The
majority of thiadiazine analogues bearing fluoro, chloro, cyano and trifluoromethylbenzylamino
substituents at the thiadiazine 2-position showed significantly improved DYRK1A binding
affinity as compared to unsubstituted benzyl group of hit 1. Importantly, p–chloro (3-2) and p-
fluoro (3-5) benzylamino thiadiazine were the most potent analogs identified with Kd of 185 nM
and 71 nM, respectively. Similarly, introduction of polar groups at the thiadiazine 2-position
with 3-pyridylmethylamino, 3-cyanobenzyl and 3-carboxyaminobenzyl groups, enhanced the
DYRK1A binding affinity in the range of 5- to 15-fold as compared to 3-1. Increasing the carbon
chain length between the 2-aminothiadiazine and the phenyl subsituent from 1 to 2 carbon atoms

ACCEPTED MANUSCRIPT
(3-22 to 3-25) improved the DYRK1A binding affinity by 4- to 5-fold. However, decreasing the
chain length (i.e. 2-phenylamino substituted thiadiazines, 3-18 to 3-21), provided no noticeable
improvement in DYRK1A binding as compared to 3-1. These data suggest that both benzylic
and phenylethyl chain lengths are well tolerated for potent DYRK1A binding of this lead series
(Figure 4). The bulkiness of substituents at the 2-position beyond phenyl, for example with
naphthylamino substituents, negatively impacted DYRK1A binding.
Since DYRK1A inhibition has been proposed to drive β-cell proliferation, the effect of
the most active DYRK1A inhibitor 3-5 on human β-cell proliferation was investigated.
Compound 3-5 induced human β-cell proliferation at 5 µM as compared to vehicle treated cells,
while also exhibiting impressive selectivity for DYRK1A over closely related kinases, DYRK1B
and DYRK2 at 10 µM.
Further improvements in DYRK1A binding affinity as well pharmacological studies
beyond DYRK1A binding of this lead series will be required to advance these translational drug
discovery efforts. While the initial hit compound was identified via docking to the DFG-out
model, several analogues designed based on this DYRK1A conformational model did not
correlate with DYRK1A binding activity. Therefore, DYRK1A co-crystallization studies and
other biophysical studies with our most potent thiadiazine analogues are in progress to
understand the binding modes of these novel thiadiazine DYRK1A inhibitor scaffolds, which
will be useful to guide further optimization to development candidate DYRK1A inhibitors. The
results of our on-going SAR for this lead scaffold and, DYRK1A biophysical studies will be
reported in due course.

ACCEPTED MANUSCRIPT
MATERIAL AND METHODS
13
1H and C NMR spectra were acquired on a Bruker DRX-600 spectrometer at 600 MHz for 1H
and 150 MHz for 13C. TLC was performed on silica coated aluminum sheets (thickness 200 µm)
or alumina coated (thickness 200 µm) aluminum sheets supplied by Sorbent Technologies and
column chromatography was carried out on Teledyne ISCO combiflash equipped with a variable
wavelength detector and a fraction collector using a RediSep Rf high performance silica flash
columns by Teledyne ISCO. LCMS and purity analysis was conducted on an Agilent
Technologies G1969A high-resolution API-TOF mass spectrometer attached to an Agilent
Technologies 1200 HPLC system. Samples were ionized by electrospray ionization (ESI) in
positive mode. Chromatography was performed on a 2.1 × 150 mm Zorbax 300SB-C18 5-ꢀm
column with water containing 0.1% formic acid as solvent A and acetonitrile containing 0.1%
formic acid as solvent B at a flow rate of 0.4 mL/min. The gradient program was as follows: 1%
B (0−1 min), 1−99% B (1− 4 min), and 99% B (4−8 min). The temperature of the column was
held at 50 °C for the entire analysis. The chemicals and reagents were purchased from Aldrich
Co., Alfa Aesar, Enamine, TCI USA, eMolecules. All solvents were purchased in anhydrous
from Acros Organics and used without further purification. Harmine CAS No. 442-51-3,
Thiadiazine 1 CAS No. 931037-76-2
.
All active compounds were synthesized independently in analytically pure form. They were
chemically stable and exhibited a dose dependent DYRK1A binding without showing any
erroneous/misleading readouts due to any aggregation, and decomposition, prevalent among
known classes of Pan Assay Interference compounds (PAINS).
Generation of DFG-out models. Models of DYRK1A in the inactive DFG-out conformation
were generated using DFGmodel[42]. Briefly, DFGmodel takes the amino acid sequence of the

ACCEPTED MANUSCRIPT
target kinase domain as input. Generation of DFG-out models is based on a manually curated set
of experimentally determined structures, sampling a range of DFG-out conformations adopted by
kinases. DFGmodel uses the structure-based sequence alignment function of T_COFFEE/
Expresso[64] v11.00.8 to align the target kinase to the template structures, and builds multi-
template homology models with MODELLER[48] v9.14. The crystal structure of DYRK1A in
the DFG-in conformation (PDBID: 3ANR[15]) was used as the input structure for DFGmodel.
50 models were built and ranked based on the size of the inhibitor-binding site calculated by
POVME[65] v2.0. 10 models with largest binding site volume were selected for virtual
screening.
Optimizing docking parameters. Molecular docking was performed using FRED[42, 66] and
Glide (Schrödinger 2015-3[67]; shown in Figures 3 and 4). We optimized the scaling parameters
used in Glide’s protein grid generation for docking inhibitors targeting DFG-out conformations.
The OPLS3 force field was used to parameterize both protein and ligands.[68] Aromatic C-H
hydrogens were considered as hydrogen-bond donors. The SP docking accuracy mode was used.
Several combinations of the scaling of van der Waals (vdW) radius for atoms with partial charge
exceeding a cutoff were examined: the default, 1.00x scaling of vdW for partial charge > ± 0.25;
0.75x scaling of vdW for partial charge > ± 0.20; and 0.75x scaling of vdW for partial charge > ±
0.15. We adapted the performance test set of kinases with known type-II and non-type-II kinase
inhibitors as described in our previous study.[42] Specifically, we used the enrichment plot to
derive the values of the area-under-curve (AUC) and the logarithmic scale of the plot
(logAUC).[54, 69] Glide docking was performed on all 50 DFG-out models of the test kinases.
Docking results from the 10 DFG-out models with largest binding site volume were processed
with the open-source cheminformatics toolkit RDKit (www.rdkit.org) and combined to generate

ACCEPTED MANUSCRIPT
a consensus ranking, represented by the best-scoring pose that can be used in the enrichment
plot. We favor the logAUC since it emphasizes the early detection of known type-II inhibitors.
Using a 0.75x scaling of vdW for atoms with partial charge > ± 0.15 yields the highest
performance in both AUC and logAUC (Tables S1, S2).
Virtual screening. 10 DYRK1A models with the largest binding site were screened against a
lead-like small molecule library (~2.2 million “available now” compounds, ZINC[53] database
downloaded in 2013). The docking results were averaged for 10 models, as described by Ung et
al.[42] We selected molecules that ranked above the 93 percentiles in at least 5 of 10 models,
represented by the best-scoring pose, resulting in ~1,000 top-ranking molecules for manual
inspection. Results were checked for unfavorable docking pose, unmatched ionization states and
tautomers, or strained conformations. 68 compounds, with an average molecular weight of 330,
were purchased and tested by in vitro activity testing.
DYRK1A Binding Assays. Compounds were tested for DYRK1A binding activity at two
different commercial kinase profiling services, Life Technologies and DiscoverX. Life
Technologies uses the FRET-based LanthaScreen® Eu Kinase Binding Assay[57] whereas
DiscoverX uses proprietary qPCR-based KINOMEscan® Assay[58, 70]. Compounds were
screened for DYRK1A activity at single concentration of 30 µM in duplicates. Similarly, the
dissociation constant Kd of the hit compounds from the initial screening was determined at
DiscoverX using their proprietary KINOMEscan® Assay[58]. Kd values are determined using
eleven serial three fold dilutions with highest concentration of 60 µM.
β-cell proliferation assay. Human pancreatic islets were obtained from the NIH/NIDDK-
supported Integrated Islet Distribution Program (IIDP) (https://iidp.coh.org). Islets were first
dispersed with Accutase (Sigma, St. Louis, MO) onto coverslips as described earlier.[9] After 2

ACCEPTED MANUSCRIPT
hours, dispersed human islet cells were treated with compound in RPMI1640 complete medium
for 96 hours. Then the cells were fixed and immunolabeled for insulin and Ki67.[9] Total
insulin-positive cells and double Ki67- plus insulin-positive cells were imaged and counted. At
least 1000 cells were counted per human islet donor.
Kinome Scan Profile. Compounds were screened against DYRK1A, DYRK1B, and DYRK2 at
single concentration of 10 µM in duplicates at DiscoverX using their proprietary KINOMEscan®
Assay.[58] The results for primary screen binding interactions are reported as '% DMSO Ctrl',
where lower values indicate stronger affinity.
Synthetic Procedures.
5-(2-Chloroacetyl)-1H-benzo[d]imidazol-2(3H)- one (2)[60]
To a suspension of aluminium chloride (5.16 g, 38.76 mmol) in DCE (20 mL) was added 2-
chloroacetyl chloride (2.34 mL, 29.8 mmol) dropwise at 0°C under Argon atmosphere and
stirred for 30 min. A solution of 2-hydroxybenzimidazole 1 (2 g, 14.9 mmol) in dichloroethane
(DCE) (5 mL) was added slowly to the above solution and stirred at 50°C for 2 hours and then,
overnight at room temperature. Upon completion of reaction monitored by LC/MS, the mixture
was poured onto ice to obtain the product as white precipitate which was filtered and washed
with water and ethyl acetate (EtOAc). Consequently, the compound was dried under high
vacuum to provide the desired product 5-(2-chloroacetyl)-1H-benzo[d]imidazol-2(3H)- one 2
1
(3.1 g, 99 %) as white solid. H-NMR (600 MHz, DMSO-d6): δ 11.13 (s, 1H), 10.98 (s, 1H),
7.69-7.67 (d, 1H), 7.49 (s, 1H), 7.05-7.04 (d, 1H), 5.13 (s, 2H) ; MS (ESI) m/z 211.02 (M+H)+.

ACCEPTED MANUSCRIPT
N-benzyl-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine hydrochloride salt
(1)[59]
A solution of 5-(2-chloroacetyl)-1H-benzo[d]imidazol-2(3H)-one 2 (0.15 g, 0.714 mmol, 1 eq.)
and N-benzylhydrazinecarbothioamide (0.15 g, 1.1 eq.) in N,N-dimethylformamide
(DMF)/acetic acid (AcOH) (2 mL/0.2 mL) was stirred at room temperature for 12 h. Upon
completion of reaction monitored by LC/MS, the mixture was concentrated under high vacuum
to remove solvent, the residue was triturated with CH2Cl2, the precipitate was wash with CH2Cl2
and dried under high vacuum to give product desired product 1 (0.22 g, 90%) as white solid. 1H-
NMR (600 MHz, DMSO-d6): δ 11.01 (s, 1H), 10.94 (s, 1H), 7.54-7.53 (d, 1H), 7.48 (s, 1H),
13
7.44-7.39 (m, 4H), 7.37-7.35 (m, 1H), 7.07- 7.05 (d, 1H), 4.71 (s, 2H), 4.22 (s, 2H); C-NMR
(150 MHz, DMSO-d6): δ 158.8, 155.4, 152.1, 135.7, 132.8, 130.3, 128.7, 127.9, 125.1, 120.7,
108.5, 106.6, 47.3, 22.2; HRMS (ESI): m/z [M + H]+ calcd for C17H16N5OS+: 338.1070, found:
338.1070; HPLC: t = 3.45 min, Purity >95%
General procedure for the synthesis of thiadiazine analogs 3[59]
A solution of 5-(2-chloroacetyl)-1H-benzo[d]imidazol-2(3H)-one 2 (0.47 mmol, 1 eq.) and N-
alkyl thiosemicarbazides (1.1 eq.) in DMF/AcOH (2 mL/0.2 mL) was stirred at room
temperature for 12 h. Upon completion of reaction monitored by LC/MS, the mixture was
concentrated under high vacuum to remove solvent and aqueous ammonia solution was added to
it. The resulting precipitate was filtered, washed with water and dried under high vacuum to give
the desired 1,3,4-thiadiazines 3.
N-benzyl-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-1)

ACCEPTED MANUSCRIPT
Yellow solid. Yield 90%. 1H-NMR (600 MHz, DMSO-d6): δ 10.76 (s, 1 H), 10.75 (s, 1 H), 7.51
(s, 1 H), 7.45 (m, 2 H), 7.34 (m, 3 H), 7.24 (m, 1 H), 6.95 (d, 1 H, J = 7.8 Hz), 4.56 (s, 2 H), 3.65
(s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.3, 139.8, 130.9, 130.1, 128.7, 128.2,
127.4, 126.6, 119.6, 108.1, 106.1, 45.4, 21.7; HRMS (ESI): m/z [M + H]+ calcd for
C17H16N5OS+: 338.1070, found: 338.1063; HPLC: t = 3.48 min, Purity >95%
.
N-(4-chlorobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-2)
1
Yellow solid. Yield 53%. H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1H), 7.51
(s, 1 H), 7.45 (m, 2 H), 7.38 (m, 3 H), 6.95 (d, 1 H, J = 8.4 Hz), 4.53 (s, 2 H), 3.65 (s, 1 H); 13C-
NMR (150 MHz, DMSO-d6): δ 155.4, 147.5, 138.8, 131.2, 131.0, 130.1, 129.3, 128.5, 128.1,
127.9, 119.6, 108.1, 106.1, 45.4, 21.8; HRMS (ESI): m/z [M + H]+ calcd for C17H15ClN5OS+:
372.0680, found: 372.0662; HPLC: t = 3.73 min, Purity >95%
N-(3-chlorobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-3)
1
Yellow solid. Yield 49%. H-NMR (600 MHz, DMSO-d6): δ 10.79 (s, 1 H), 10.77 (s, 1H), 7.46
(d, 2 H, J = 7.2 Hz), 7.41 (s, 1 H), 7.36 (d, 1 H, J = 7.8 Hz), 7.33 (d, 2 H, J = 6.6 Hz), 6.96 (d, 1
H, J = 8.4 Hz), 4.56 (s, 2 H), 3.72 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.7,
142.3, 132.9, 131.1, 130.1, 128.3, 127.2, 126.7, 126.1, 119.7, 108.1, 106.1, 45.4, 21.8; HRMS
(ESI): m/z [M + H]+ calcd for C17H15ClN5OS+: 372.0680, found: 372.0667; HPLC: t = 3.75 min,
Purity >95%
N-(2-chlorobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-4)
1
Yellow solid. Yield 57%. H-NMR (600 MHz, DMSO-d6): δ 10.79 (s, 1 H), 10.77 (s, 1H), 7.46
13
(m, 3 H), 7.32 (m, 3 H), 6.96 (d, 1 H, J = 9.0 Hz), 4.61 (s, 2 H), 3.73 (s, 2 H); C-NMR (150

ACCEPTED MANUSCRIPT
MHz, DMSO-d6): δ 155.4, 148.1, 136.2, 132.0, 131.3, 130.1, 129.1, 128.6, 128.0, 127.5, 127.1,
119.8, 108.1, 106.2, 44.7, 21.9; HRMS (ESI): m/z [M + H]+ calcd for C17H15ClN5OS+: 372.0680,
found: 372.0668; HPLC: t = 3.62 min, Purity >95%
N-(4-fluorobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-5)
1
Yellow solid. Yield 36%. H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1H), 7.45
(m, 2 H), 7.39 (m, 2 H), 7.15 (t, 3 H, J = 9.0 Hz), 6.94 (d, 1 H, J = 8.4 Hz), 4.53 (s, 2 H), 3.67 (s,
2 H); 13C-NMR (150 MHz, DMSO-d6): δ 161.9, 160.3, 155.4, 148.0, 147.4, 136.0, 131.0, 130.1,
129.8, 129.4, 129.3, 128.6, 119.6, 114.9, 114.8, 108.1, 106.1, 45.4, 21.8; HRMS (ESI): m/z [M +
H]+ calcd for C17H15FN5OS+: 356.0976, found: 356.0983; HPLC: t = 3.57 min, Purity >95%.
N-(3-fluorobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-6)
1
Yellow solid. Yield 62%. H-NMR (600 MHz, DMSO-d6): δ 10.78 (s, 1 H), 10.77 (s, 1H), 7.46
(d, 2 H, J = 7.2 Hz), 7.38 (m, 1 H), 7.17 (m,2 H), 7.08 (m, 1 H), 6.96 (d, 1 H, J = 7.8 Hz), 4.56
(s, 2 H), 3.70 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 163.0, 161.4, 155.4, 147.8, 142.7,
131.1, 130.1, 128.3, 123.4, 119.7, 114.1, 113.5, 106.1, 45.3, 21.8; HRMS (ESI): m/z [M + H]+
calcd for C17H15FN5OS+: 356.0976, found: 356.0975; HPLC: t = 3.54 min, Purity >95%.
N-(2-fluorobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-7)
1
Yellow solid. Yield 44%. H-NMR (600 MHz, DMSO-d6): δ 10.81 (s, 1 H), 10.79 (s, 1H), 7.46
(m, 3 H), 7.33 (m, 1 H), 7.20 (m,2 H), 6.96 (d, 1 H, J = 8.4 Hz), 4.61 (s, 2 H), 3.76 (s, 2 H); 13C-
NMR (150 MHz, DMSO-d6): δ 160.9, 159.3, 155.4, 131.4, 130.1, 129.8, 129.1, 124.3, 119.8,
115.1, 108.1, 106.2, 21.8; HRMS (ESI): m/z [M + H]+ calcd for C17H15FN5OS+: 356.0976,
found: 356.0989; HPLC: t = 3.48 min, Purity >95%.
N-(4-trifluoromethylbenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine
(3-8)

ACCEPTED MANUSCRIPT
Yellow solid. Yield 33%. 1H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1 H), 7.71
(d, 2 H, J = 7.8 Hz), 7.56 (d, 2 H, J = 7.8 Hz), 7.46 (d, 2 H, J = 7.8 Hz), 6.95 (d, 1 H, J = 9.0 Hz),
4.63 (s, 2 H), 3.66 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.5, 144.9, 131.0,
130.0, 128.5, 128.0, 127.4, 125.5, 125.0, 124.6, 123.4, 119.6, 108.1, 106.1, 45.5, 21.8; HRMS
(ESI): m/z [M + H]+ calcd for C18H15F3N5OS+: 406.0944, found: 406.0934; HPLC: t = 3.91 min,
Purity >95%.
N-(3-trifluoromethylbenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine
(3-9)
Yellow solid. Yield 54%. 1H-NMR (600 MHz, DMSO-d6): δ 10.78 (s, 1 H), 10.77 (s, 1 H), 7.70
(m, 1 H), 7.68 (d, 2 H, J = 7.2 Hz), 7.61 (m, 2 H), 7.46 (m 2 H), 6.95 (d, 1 H, J = 8.4 Hz), 4.64
(s, 2 H), 3.68 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.5, 141.4, 131.5, 131.0,
130.1, 129.3, 128.5, 123.8, 123.4, 119.6, 108.2, 106.1, 44.9, 21.8; HRMS (ESI): m/z [M + H]+
calcd for C18H15F3N5OS+: 406.0944, found: 406.0924; HPLC: t = 3.87 min, Purity >95%.
N-(2-trifluoromethylbenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine
(3-10)
Yellow solid. Yield 23%. 1H-NMR (600 MHz, DMSO-d6): δ 10.78 (s, 1 H), 10.77 (s, 1 H), 7.73
(d, 1 H, J = 7.8 Hz), 7.67 (d, 2 H, J = 7.2 Hz), 7.61 (m, 1 H), 7.48 (m 2 H), 6.95 (d, 1 H, J = 8.4
Hz), 4.75 (s, 2 H), 3.72 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.7, 138.0, 132.6,
131.0, 130.1, 128.7, 128.5, 127.2, 126.1, 125.9, 123.6, 119.7, 108.1, 106.1, 41.9, 21.8; HRMS
(ESI): m/z [M + H]+ calcd for C18H15F3N5OS+: 406.0944, found: 406.0927; HPLC: t = 3.80 min,
Purity >95%.

ACCEPTED MANUSCRIPT
N-(4-cyanobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-11)
Yellow solid. Yield 45%. 1H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1H), 7.81
(d, 2 H, J = 8.4 Hz), 7.65 (s, 1 H), 7.54 (d, 2 H, J = 7.8 Hz), 7.46 (m, 2 H), 6.94 (d, 1 H, J = 8.4
Hz), 4.62 (s, 2 H), 3.67 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.5, 146.0, 132.6,
132.2, 131.7, 131.0, 130.1, 128.5, 128.1, 127.7, 119.6, 118.9, 109.3, 108.1, 106.1, 45.1, 21.8;
HRMS (ESI): m/z [M + H]+ calcd for C18H15N6OS+: 363.1023, found: 363.1006; HPLC: t = 3.30
min, Purity >95%.
N-(3-cyanobenzyl)-5-(benzo[]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-12)
Yellow solid. Yield 45%. 1H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.74 (s, 1H), 7.79
(s, 1 H), 7.72 (m, 2 H), 7.56 (t,1 H, J = 7.8 Hz), 7.46 (m, 2 H), 6.96 (d, 1 H, J = 8.4 Hz), 4.59 (s,
2 H), 3.71 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4, 147.6, 141.7, 132.4, 131.0, 130.9,
130.4, 130.1, 129.4, 128.5, 119.7, 118.9, 111.1, 108.1, 106.1, 44.9, 21.8; HRMS (ESI): m/z [M +
H]+ calcd for C18H15N6OS+: 363.1023, found: 363.1015; HPLC: t = 3.34 min, Purity >95%.
N-(pyridine-3yl)methyl-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-13)
Yellow solid. Yield 43%. 1H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1H), 8.57
(s, 1 H), 8.45 (s, 1 H), 7.76 (d, 1 H, J =6.6 Hz), 7.57 (s, 1 H), 7.46 (m, 1 H), 7.36 (m, 1 H), 6.96
(d, 1 H, J = 8.4 Hz), 4.57 (s, 2 H), 3.66 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): δ 155.4,
149.4, 148.9, 148.4, 148.0, 147.5, 135.2, 131.0, 130.1, 128.6, 123.4, 119.6, 108.1, 106.1, 43.3,
21.8; HRMS (ESI): m/z [M + H]+ calcd for C16H15N6OS+: 339.1023, found: 339.1020; HPLC: t
= 1.25 min, Purity >95%.
N-(pyridine-4yl)methyl-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-14)

ACCEPTED MANUSCRIPT
Yellow solid. Yield 34%. 1H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1H), 8.51
(m, 2 H), 7.46 (m, 2 H), 7.34 (m, 2 H), 6.96 (d, 1 H, J = 9 Hz), 4.56 (s, 2 H), 3.70 (s, 2 H); 13C-
NMR (150 MHz, DMSO-d6): δ 155.4, 150.2, 149.5, 149.0, 131.0, 130.1, 128.5, 122.8, 122.2,
119.7, 108.2, 106.1, 45.2, 21.8; HRMS (ESI): m/z [M + H]+ calcd for C16H15N6OS+: 339.1023,
found: 339.1004; HPLC: t = 1.23 min, Purity >95%.
N-(3-carboxyaminobenzyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine
(3-15)[61]
To a solution of 3.12 (0.091 mmol) in DMSO (1 mL) was added 50 % hydrogen peroxide
solution (0.013 mL) at 0 oC followed by potassium carbonate (0.015 eq.). The reaction mixture
was allowed to warm up to room temperature and stirred overnight. Upon the completion of
reaction, the reaction mixture was vacuum dried and purified using flash chromatography with
mixture of methanol/dichloromethane/ammonia(10:89:1) as eluent to get the final product as
yellow solid. Yield 42%. 1H-NMR (600 MHz, DMSO-d6): δ 10.77 (s, 1 H), 10.76 (s, 1H), 7.95
(m, 2 H), 7.86 (m, 1 H), 7.75 (m,1 H), 7.51 (m, 1 H), 7.47 (m, 2 H), 7.40 (m, 1 H), 7.34 (m, 1 H),
6.96 (d, 1 H, J = 7.8 Hz), 4.59 (s, 2 H), 3.68 (s, 2 H); 13C-NMR (150 MHz, DMSO-d6): 167.9,
155.4, 147.3, 139.9, 134.2, 131.0, 130.3, 130.0, 128.6, 128.0, 126.3, 124.2, 119.6, 108.2, 106.1,
45.9, 21.7; HRMS (ESI): m/z [M + H]+ calcd for C18H17N6O2S+: 381.1128, found: 381.1110;
HPLC: t = 1.80 min, Purity >95%.
N-(1-phenylethyl)-5-(benzo[d]imidazol-2(3H)-one)-6H-1,3,4- thiadiazin-2-amine (3-16)
Yellow solid. Yield 41%. 1H-NMR (600 MHz, DMSO-d6): δ 10.76 (s, 1 H), 10.75 (s, 1H), 7.42
(m, 2 H), 7.36 (d, 2 H, J = 7.2 Hz), 7.32 (m, 2 H), 7.21 (m,1 H), 6.94 (d, 1 H, J = 7.8 Hz), 5.20
(s, 1 H), 3.72 (s, 1 H), 3.52 (s, 1 H), 1.43 (d, 3 H, J = 7.2 Hz); 13C-NMR (150 MHz, DMSO-d6):
δ 155.4, 147.1, 145.4, 130.9, 130.0, 128.6, 128.1, 126.4, 126.0, 118.5, 108.0, 106.0, 52.1, 23.3,